Prefer midcap pharma space: Hemindra Hazari

Hemindra Hazari, independent market expert told CNBC-TV18, "Midcap pharma is going to be a better bet because large cap pharma has been a disappointment so far. In certain of these large cap pharma names I think US sales were company specific issues. I think midcap pharma like Torrent Pharma or Glenmark Pharma are going to have some good product launches.""You are going to see equity investors already come in Glenmark Pharma and debt will be significantly reduced like we just saw for DLF probably. So, that could result in a further re-rating of the stock if there is a debt reduction," he said.